Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D S Zaharko

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Journal of Immunopharmacology|January 1, 1985
Immunological concepts and the combination of cyclophosphamide with 5-aza-2'-deoxycytidine on L1210 in vivoD S Zaharko
Cancer Chemotherapy Reports. Part 3|May 1, 1972
PharmacokineticsD S Zaharko
Annals of the New York Academy of Sciences|November 30, 1971
Tissue distribution of folate antagonistsV T Oliverio, D S Zaharko
Cancer Treatment Reports|December 1, 1984
Effects of dose and duration of exposure on 5-aza-2'-deoxycytidine cytotoxicity for L1210 leukemia in vitroJ M Covey, D S Zaharko
Cancer Research|November 1, 1983
Modification of chemotherapeutic effects on L1210 cells using hematoporphyrin and lightS P Creekmore, D S Zaharko
Journal of the National Cancer Institute|November 1, 1983
Modulation of deoxycytidine metabolism in vivo with high-dose thymidine in miceD S Zaharko, J M Covey
Biochemical Pharmacology|November 1, 1970
Reinvestigation of methotrexate metabolism in rodentsD S Zaharko, V T Oliverio
European Journal of Cancer & Clinical Oncology|January 1, 1985
Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in miceJ M Covey, D S Zaharko
Cancer Treatment Reports|October 1, 1984
Effects of 5-aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing miceD S Zaharko, J M Covey
Investigational New Drugs|January 1, 1985
Arabinosyl-5-azacytosine: plasma kinetics and therapeutic response (L1210) in vitro and in vivo in miceD S Zaharko, J M Covey
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Journal of Immunopharmacology|January 1, 1985
Immunological concepts and the combination of cyclophosphamide with 5-aza-2'-deoxycytidine on L1210 in vivoD S Zaharko
Cancer Chemotherapy Reports. Part 3|May 1, 1972
PharmacokineticsD S Zaharko
Annals of the New York Academy of Sciences|November 30, 1971
Tissue distribution of folate antagonistsV T Oliverio, D S Zaharko
Cancer Treatment Reports|December 1, 1984
Effects of dose and duration of exposure on 5-aza-2'-deoxycytidine cytotoxicity for L1210 leukemia in vitroJ M Covey, D S Zaharko
Cancer Research|November 1, 1983
Modification of chemotherapeutic effects on L1210 cells using hematoporphyrin and lightS P Creekmore, D S Zaharko
Journal of the National Cancer Institute|November 1, 1983
Modulation of deoxycytidine metabolism in vivo with high-dose thymidine in miceD S Zaharko, J M Covey
Biochemical Pharmacology|November 1, 1970
Reinvestigation of methotrexate metabolism in rodentsD S Zaharko, V T Oliverio
European Journal of Cancer & Clinical Oncology|January 1, 1985
Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in miceJ M Covey, D S Zaharko
Cancer Treatment Reports|October 1, 1984
Effects of 5-aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing miceD S Zaharko, J M Covey
Investigational New Drugs|January 1, 1985
Arabinosyl-5-azacytosine: plasma kinetics and therapeutic response (L1210) in vitro and in vivo in miceD S Zaharko, J M Covey
Pageof 6